FDA grants orphan drug status to selumetinib for neurofibromatosis type 1 (NF1) treatment

Main|Search|PHGKB



Last Posted: May 20, 2018

---

• FDA grants orphan drug status to selumetinib for neurofibromatosis type 1 (NF1) treatment  
  NCI Cancer Research, May 2018
• Genotype-phenotype correlation in paediatric pheochromocytoma and paraganglioma: a single centre experience from India.  
  Khadilkar Kranti et al. Journal of pediatric endocrinology & metabolism : JPEM 2017 May 30(5) 575-581
• Non-invasive prenatal diagnosis of paternally inherited disorders from maternal plasma: detection of NF1 and CFTR mutations using droplet digital PCR.  
  Gruber Aurélia et al. Clinical chemistry and laboratory medicine 2018 Apr 56(5) 728-738
• Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer.  
  Wang Xia et al. Genes, chromosomes & cancer 2018 Jan 57(1) 19-27
• First report of the efficacy of vestibular rehabilitation in improving function in patients with Neurofibromatosis type 2: an observational cohort study in a clinical setting.  
  Emmanouil Beatrice et al. Disability and rehabilitation 2018 Mar 1-7
• Families dealing with the uncertainty of genetic disorders: the case of Neurofibromatosis Type 1.  
  Carrieri Daniele et al. Sociology of health & illness 2016 Jun 38(5) 753-67
• Predictive genetic testing in children: constitutional mismatch repair deficiency cancer predisposing syndrome.  
  Bruwer Zandrè et al. Journal of genetic counseling 2014 Apr 23(2) 147-55
• Genetic Severity Score predicts clinical phenotype in NF2.  
  Halliday Dorothy et al. Journal of medical genetics 2017 Aug
• Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults.  
  Pathmanaban Omar N et al. JAMA neurology 2017 Jul
• Clinical application of next-generation sequencing for the diagnosis of segmental neurofibromatosis.  
  Ko Younhee et al. Journal of dermatological science 2017 Jul

more